Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fair Trade Is Not FDA's Expertise, Amarin Says In Omega-3 Ingredients Filing

Executive Summary

Maker of Rx Vascepa says it's not asking trade panel to interpret the FD&C Act, but to investigate whether some omega-3 ingredient suppliers and marketers are failing to fulfill "certain marketplace expectations about the nature" of their products. ITC is about to decide whether to investigate complaint, which could impact a number of dietary supplement firms.

Advertisement

Related Content

Trade Panel Bolsters FDA's View In Amarin Omega-3 Complaint
Trade Panel Bolsters FDA's View In Amarin Omega-3 Complaint
FDA Objects To Amarin Trade Complaint Against Omega-3 Ingredients
Amarin Makes Flawed Argument In Bid To Drain Omega-3 Market – CRN
Amarin's Omega-3 Fair Trade Complaint Questions US Dietary Ingredient Standards

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121800

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel